

Ortho-substituted iodobenzenes as novel organocatalysts for bromination of alkenes†

D. Christopher Braddock,^{*a} Gemma Cansell^a and Stephen A. Hermitage^b


Received (in Cambridge, UK) 21st March 2006, Accepted 20th April 2006

First published as an Advance Article on the web 3rd May 2006

DOI: 10.1039/b604130b


Suitably *ortho*-substituted iodobenzenes act as organocatalysts for the transfer of electrophilic bromine from *N*-bromosuccinimide to alkenes *via* the intermediacy of bromoiodinanes.

Recently we demonstrated that bromoiodinanes **1** and **2** are readily prepared in a single step by reaction of *N*-bromosuccinimide (NBS) with carbinols **3** and **4** respectively.¹ Subsequently, bromoiodinane **1** proved to be an efficient electrophilic bromine source for transfer to arenes or alkenes. A significant observation of these bromination reactions is that the only by-product observed is carbinol **3**. Since carbinol **3** is converted directly into **1** by the action of NBS, and given that carbinol **3** is the sole by-product of the subsequent bromination event, the bromination reaction should be able to be rendered catalytic in carbinol **3**. In this communication we demonstrate that the reaction can indeed be rendered catalytic in carbinol **3** with bromoiodinane **1** acting as the actual catalytic brominating agent. We also show that superior catalysts are available by increasing the nucleophilicity of the *ortho*-substituent. This is a rare example of a system which has a catalytic cycle with iodine in the I(I) and I(III) oxidation states.^{2,3} To the best of our knowledge it also constitutes the first organocatalytic transfer of electrophilic bromine to alkenes.




We chose to examine the bromolactonisation of 4-pentenoic acid **5** into bromolactone **6** for the purpose of developing a catalytic bromination of alkenes (Table 1). In the control experiments without any catalyst (entry 1) the extent of bromolactonisation after 0.5 h is insignificant. After 15 h, 20% bromolactonisation of **5** into **6** has occurred. Thus the background bromination rate using NBS only is slow. The use of ditrifluoromethylcarbinol **4** as catalyst (25 mol%) resulted in a modest increase in conversion of **5** into **6** to 32%. At the same catalyst loading carbinol **3** catalysed the reaction to quantitative conversion in the same time period. The cyclisation is extremely clean and, apart from resonances for the catalyst and succinimide, only the desired product **6** could be detected by ¹H and ¹³C NMR. The difference between the catalytic activities of

3 and **4** may be attributed to the more nucleophilic oxygen atom of **3**. A catalytic cycle invoking the intermediacy of the bromoiodinane **1** is shown below (Scheme 1).



Scheme 1 Catalytic cycle involving bromoiodinane **1**.

On the basis of the above results, it is to be expected that other *ortho*-substituted iodobenzenes with pendant nucleophilic groups should function as catalysts by formation of bromoiodinane intermediates.



Accordingly, a series of iodobenzoic acids and derivatives were screened (Table 1, entries 4–12). 2-Iodobenzoic acid **7a**† proved to be superior as a catalyst (10 mol%) giving quantitative conversion to **6** in 6 h at room temperature. Amino derivative **7b**,⁵ which should boost the nucleophilicity of the carboxylic acid group by resonance proved still more superior. 3-Iodobenzoic acid (**7c**), where the carboxylic acid group is now *meta* to the iodine gave no increase in conversion relative to the control experiment, consistent with the need to form a bromoiodinane with an O–I–Br

^aDepartment of Chemistry, Imperial College London, London, UK SW7 2AZ. E-mail: c.braddock@imperial.ac.uk; Fax: +44(0)2075945805; Tel: +44(0)2075945772

^bGlaxoSmithKline Ltd, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK SG1 2NY

† Electronic supplementary information (ESI) available: Preparation and full characterising details of catalysts **7g** and **7i**, and substrates **10–14**. See DOI: 10.1039/b604130b

Table 1 Catalytic bromolactonisation of **5** into **6**^a

Entry	Catalyst	Loading (mol%)	Time/h	Conversion ^c (%)
1	—	—	0.5 (15)	2 (20)
2	4	25	15	32
3	3	25	15	100
4	7a	10	6	100
5	7b	10	3	100
6	7c	10	24	25
7	7d	10	19	53
8	7e	10	2	72
9 ^b	7f	10	0.5	100
10	7g	10	0.33	100
11	7h	10	<1.5	100
12	7i	10	<0.5	100

^a All reactions performed with 1.0 eq NBS in CDCl₃ at rt. ^b 1.2 eq NBS. ^c Conversion determined by ¹H NMR.
















three-centre four-electron bond. Control experiments with just iodobenzene or benzoic acid as potential catalysts (not shown in Table 1) gave no increase in conversion. Further evidence for the intermediacy of a bromiodinane comes from the use of 3-methyl-2-iodobenzoic acid **7d** as catalyst, where the sp³-hybridised carbon atom of the methyl group at the 3-position would engender a steric clash with the bromine atom in the putative bromiodinane. This

iodobenzene acts as a catalyst but the conversion relative to 2-iodobenzoic acid is much reduced.

Incorporating a more nucleophilic oxygen atom as part of an amide group *ortho* to the iodo group gives even more superior catalysts. The inductive effect of added alkyl groups on moving along the 1° (**7e**),⁶ 2° (**7f**)⁷ and 3° (**7g**)⁸ amide series is also clearly evident. Dicarboxylic acid **7h**⁸—a catalyst with a pendant nucleophilic group at both *ortho* positions of the iodobenzene—was found to be a superior catalyst compared to 2-iodobenzoic acid **7a**. Finally, amidine **7i**⁹ proved to be an excellent catalyst too, as expected on the basis of nucleophilicity. The above experiments demonstrate that (i) the pendant functional group is required to be positioned *ortho* to the iodine atom on the benzene ring, (ii) for a given *ortho*-positioned functional group increasing its nucleophilicity results in superior catalysts and (iii) substitution of an sp³-hybridised group at the other *ortho* position retards the catalytic ability. All these effects are consistent with the intermediacy of a bromiodinane which is the electrophilic bromine source. Further, catalysts of higher activity are available by introduction of two pendant nucleophilic groups at both *ortho* positions of the iodobenzene *cf.* **7h** vs. **7a**.

A series of other bromolactonisation substrates **8–14**¹⁰ were screened using highly active catalyst **7i** (Table 2). All the substrates cyclised smoothly to give bromolactone products **15–22**.^{**} The

Table 2 Catalytic bromolactonisation of substrates **8–14** with catalyst **7i**^a

Entry	Substrate	Time/h	Product(s)	Conversion ^b (%)	Isolated yield ^c (%)
1	 8	1	 15	100 (<5)	89
2	 9	0.5	 16	100 (0)	91
3	 10	0.5	 17	100 (14)	93
4	 11	0.5	 18	100 (100)	98
5	 12	1.5	 19  20	100 (13) ^d	83 ^e
6	 13	1	 21	100 (12) ^f	81 ^g
7	 14	0.25	 22	100 (0)	90

^a All reactions performed with 10 mol% **7i** and 1.0 eq NBS in CDCl₃ at rt. ^b Conversion determined by ¹H NMR. The percentage conversion in the control experiment without catalyst is given in parentheses. ^c Isolated yield after chromatography. ^d The ratio of **19** : **20** was 1 : 1 in the catalysed reaction and 8 : 2 in the uncatalysed reaction. ^e Combined yield: 43% of **19**; 40% of **20**. ^f A minor isomer (<10%) was observed in both the catalysed and uncatalysed reaction. ^g A 6-ring lactone was isolated in 6% yield. It was identified by the characteristic IR stretch at 1719 cm⁻¹.

products are all consistent with the intermediacy of bromonium ions followed by intramolecular attack of the nucleophilic carboxylate. Two factors are at play in determining the ring-size of the bromolactone product. The nucleophile prefers to attack the bromonium ion at its most substituted carbon, consistent with the stabilisation of partial positive charge there. Secondly, the *exo* ring-closing process is preferred to the *endo* mode. With the exception of substrate **12**, both these factors are reinforcing and a single bromolactone product is observed. For substrate **12**, a “mismatched” substrate, both the 5 and 6-ring lactones are observed. It is interesting to note that the product distribution changes markedly in the catalysed *versus* uncatalysed reaction for this substrate. Finally, the isomeric *E* and *Z* unsaturated acids **13** and **14** give two different diastereoisomers, consistent with the stereospecific ring-opening of a bromonium ion. For all the bromolactonisation products, the ring sizes were readily identified by inspection of the lactone stretching frequency in the IR spectra. For example 5-ring lactone **20** displays a stretching frequency of 1780 cm⁻¹, whereas 6-ring lactone **19** shows a characteristic stretch at 1724 cm⁻¹.

In conclusion we have developed the first organocatalytic method for the transfer of electrophilic bromine to alkenes. We invoke a catalytic cycle involving I(I) and I(III) oxidation states. These results should provide a platform for the development of a highly efficient asymmetric bromination reaction of prochiral alkenes.

We thank the EPSRC and GlaxoSmithKline Ltd. for an Industrial CASE award to G.C.

Notes and references

‡ **7a**, **7c** and **7d** are all commercially available iodobenzoic acids.

§ **7g** was prepared by *N,N*-alkylation of benzamide **7e** with bromobutane. Full details are given in the ESI.†

¶ Amidine **7i** was prepared by the method of Daoust and Lessard for amidine preparation from amides [ref. 9] starting from 2-iodo-*N*-phenylbenzamide [ref. 10]. Full details are given in the ESI.†

|| Acids **8–14** are all known compounds. 5-Hexenoic acid **8** and 2-cyclopentene-1-acetic acid **9** are commercially available. γ,δ -Unsaturated acids **11**, **12** and **13** are prepared by Johnson–Claisen rearrangement [ref. 11] of the appropriately substituted prop-2-en-1-ol with triethylorthoformate, followed by hydrolysis of the resulting ethyl ester. Acid **10** is prepared by the action of a Wittig reagent on ethyl 4-oxo-4-phenylbutyrate, followed by ester hydrolysis. *Z*-Unsaturated acid **14**, was prepared by the Wittig reaction of the phosphonium salt of ethyl 4-bromobutyrate with butyraldehyde followed by ester hydrolysis. Full details are given in the ESI.†

** Data for bromolactones **15–22**: 6-Bromomethyltetrahydropyran-2-one (**15**): *R*_f 0.30 (2 : 8, EtOAc : petroleum ether); FT IR (NaCl) ν_{max} 1738 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 4.52–4.42 (m, 1H, OCH), 3.55–3.41 (m, 2H, CH₂Br), 2.65–2.37 (m, 2H, CH₂), 2.16–1.61 (m, 4H, CH₂CH₂); ¹³C NMR (68 MHz, CDCl₃) δ 170.4, 78.6, 33.8, 29.4, 26.3, 18.1; MS (CI⁺) 212, 210 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₆H₁₃⁷⁹BrNO₂ 210.0130, found 210.0120.

6-Bromohexahydrocyclopenta[*b*]furan-2-one (**16**): *R*_f 0.30 (1 : 9, EtOAc : petroleum ether); FT IR (NaCl) ν_{max} 1778 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 5.04 (d, *J* = 6.2 Hz, 1H, OCH), 4.41 (d, *J* = 4.5 Hz, 1H, CHBr), 3.20–3.03 (m, 1H, CH), 2.85 (dd, *J* = 18.5, 10.2 Hz, 1H, C(O)CHH), 2.47–2.00 (m, 4H, CH₂), 1.62–1.49 (m, 1H, CHH); ¹³C NMR (68 MHz, CDCl₃) δ 176.5, 90.5, 52.9, 36.0, 35.9, 33.1, 31.4; MS (CI⁺) 224, 222 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₇H₁₃⁷⁹BrNO₂ 222.0130, found 222.0122.

5-Bromomethyl-5-phenyldihydrofuran-2-one (**17**): *R*_f 0.13 (4 : 6, petroleum ether : CH₂Cl₂); FT IR (NaCl) ν_{max} 1783 cm⁻¹; ¹H NMR

(270 MHz, CDCl₃) δ 7.40–7.35 (m, 5H, ArH), 3.72 (d, *J* = 11.3 Hz, 1H, HHCBr), 3.67 (d, *J* = 11.3, 1H, HHCBr), 2.85–2.73 (m, 2H, CH₂), 2.60–2.44 (m, 2H, CH₂); ¹³C NMR (68 MHz, CDCl₃) δ 175.6, 140.8, 128.9, 128.8, 125.0, 86.5, 41.2, 32.5, 29.2; MS (CI⁺) 274, 272 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₁₁H₁₅⁷⁹BrNO₂ 272.0286, found 272.0274; Anal. calcd for C₁₁H₁₁BrO₂ C, 51.79; H, 4.35; found: C, 51.86; H, 4.39.

5-(Bromomethyl)-5-methyl- γ -butyrolactone (**18**): *R*_f 0.26 (3 : 7, petroleum ether : CH₂Cl₂); FT IR (NaCl) ν_{max} 1776 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.52 (d, *J* = 10.8 Hz, 1H, CHHBr), 3.44 (d, *J* = 10.8 Hz, 1H, CHHBr), 2.61–2.68 (m, 2H, CH₂), 2.41–2.29 (m, 1H, CHH), 2.13–1.97 (m, 1H, CHH₂), 1.54 (s, 3H, CH₃); ¹³C NMR (68 MHz, CDCl₃) δ 175.9, 84.2, 39.6, 31.6, 29.3, 25.5; MS (CI⁺) 212, 210 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₆H₁₃⁷⁹BrNO₂ 210.0130, found 210.0125.

5-Bromo-6,6-dimethyltetrahydropyran-2-one (**19**): mp 45–47 °C; *R*_f 0.30 (3 : 7, petroleum ether : CH₂Cl₂); FT IR (NaCl) ν_{max} 1724 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 4.19 (dd, *J* = 8.0, 4.0 Hz, 1H, CHBr), 2.80 (ddd, *J* = 18.4, 7.9, 6.3 Hz, 1H, CHH), 2.60 (ddd, *J* = 18.5, 7.5, 6.3 Hz, 1H, CHH); 2.52–2.24 (m, 2H, CH₂), 1.53 (s, 6H, C(CH₃)₂); ¹³C NMR (68 MHz, CDCl₃) δ 169.2, 83.3, 52.5, 28.2, 27.8, 27.4, 26.1; MS (CI⁺) 226, 224 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₇H₁₅⁷⁹BrNO₂ 224.0286, found 224.0279.

5-(1-Bromo-1-methylethyl)- γ -butyrolactone (**20**): mp 43–45 °C; *R*_f 0.40 (3 : 7, petroleum ether : CH₂Cl₂); FT IR (NaCl) ν_{max} 1780 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 4.30 (t, *J* = 7.2 Hz, 1H, OCH), 2.72–2.48 (m, 2H, CH₂), 2.43–2.16 (m, 2H, CH₂); 1.76 (s, 3H, CH₃), 1.74 (s, 3H, CH₃); ¹³C NMR (68 MHz, CDCl₃) δ 176.5, 85.9, 65.6, 30.5, 29.5, 28.7, 24.6; MS (CI⁺) 226, 224 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₇H₁₅⁷⁹BrNO₂ 224.0286, found 224.0280; Anal. calcd for C₇H₁₁BrO₂ C, 40.60; H, 5.35; found: C, 40.74 H, 5.46.

(1*R**,2*S**)-5-(1-Bromobutyl)- γ -butyrolactone (**21**): *R*_f 0.34 (4 : 6, petroleum ether : CH₂Cl₂); FT IR (NaCl) ν_{max} 1781 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 4.50 (q, *J* = 7.0, 1H, HCO), 4.04 (ddd, *J* = 10.0, 6.9, 3.4 Hz, 1H, HCBr), 2.67–2.35 (m, 3H, CH₂), 2.21–2.05 (m, 1H, CHH), 1.98–1.85 (m, 1H, CHH), 1.81–1.54 (m, 2H, CH₂), 1.52–1.33 (m, 1H, CHH), 0.92 (t, *J* = 7.3 Hz, 3H, CH₃); ¹³C NMR (68 MHz, CDCl₃) δ 176.4, 81.4, 57.6, 36.7, 28.6, 26.0, 20.4, 13.4; MS (CI⁺) 240, 238 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₈H₁₇⁷⁹BrNO₂ 238.0443, found 238.0442.

(1*S**,2*S**)-5-(1-Bromobutyl)- γ -butyrolactone (**22**): *R*_f 0.32 (4 : 6, petroleum ether : Et₂O); FT IR (NaCl) ν_{max} 1782 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 4.61 (ddd, *J* = 7.0, 6.0, 3.0 Hz, 1H, OCH), 4.03 (ddd, *J* = 8.0, 5.0, 3.0 Hz, 1H, HCBr), 2.66 (ddd, 17.5, 11.0, 6.0 Hz, 1H, CHH), 2.53 (dd, *J* = 10, 7.5 Hz, 1H, CHH), 2.47–2.31 (m, 1H, CHH), 2.22–2.09 (m, 1H, CHH), 1.94–1.75 (m, 2H, CH₂), 1.70–1.54 (m, 1H, CHH), 1.51–1.32 (m, 1H, CHH), 0.91 (t, *J* = 7.0 Hz, 3H, CH₃); ¹³C NMR (68 MHz, CDCl₃) δ 176.6, 81.0, 57.8, 36.6, 28.4, 25.5, 20.9, 13.4; MS (CI⁺) 240, 238 (M + NH₄⁺); HRMS calcd for (M + NH₄) C₈H₁₇⁷⁹BrNO₂ 238.0443, found 238.0433; Anal. calcd for C₈H₁₃BrO₂ C, 43.36; H, 5.93; found: C, 43.53; H, 5.93.

- D. C. Braddock, G. Cansell, S. A. Hermitage and A. J. P. White, *Chem. Commun.*, 2006, 1442–1444.
- T. Dohi, A. Maruyama, M. Yoshimura, K. Morimoto, H. Tohma and Y. Kita, *Angew. Chem., Int. Ed.*, 2005, **44**, 6193–6196.
- M. Ochiai, Y. Takeuchi, T. Katayama, T. Sueda and K. Miyamoto, *J. Am. Chem. Soc.*, 2005, **127**, 12244–12245.
- D. C. Braddock, G. Cansell and S. A. Hermitage, *Synlett*, 2004, 461–464.
- J. Protiva, V. Krecek, B. Maca, J. Urban, M. Budesinsky and M. Prochazka, *Collect. Czech. Chem. Commun.*, 1989, **54**, 1012–1018.
- A. Gescher, M. F. G. Stevens and C. P. Turnbull, *J. Chem. Soc., Perkin Trans. 1*, 1977, 103–106.
- C. S. Cho, X. Wu, L. H. Jiang, S. C. Shim, H.-J. Choi and T. J. Kim, *J. Heterocycl. Chem.*, 1998, **35**, 265.
- K. P. Shelly, S. Venimadhavan, K. Nagarajan and R. Stewart, *Can. J. Chem.*, 1989, **67**, 1274–1282.
- B. Daoust and J. Lessard, *Can. J. Chem.*, 1995, **73**, 362–374.
- R. J. Perry and S. R. Turner, *J. Org. Chem.*, 1991, **56**, 6573–6579.
- W. S. Johnson, L. Werthemann, W. R. Bartlett, T. J. Brockson, T.-T. Li, D. J. Faulkner and M. R. Petersen, *J. Am. Chem. Soc.*, 1970, **92**, 741–743.